REGULATORY FRAMEWORK FOR COMPULSORY LICENSING OF LIFE-SAVING BIOLOGICS IN JAPAN

1. INTRODUCTION

Compulsory licensing is a legal mechanism through which a government authorizes a third party to use a patented invention without obtaining the patent holder's consent, subject to statutory conditions and appropriate remuneration.

In the biotechnology and pharmaceutical sectors, compulsory licensing can become important when patented life-saving biologics, including vaccines, monoclonal antibodies, therapeutic proteins, blood-derived products and other biological medicines, are insufficiently available or cannot be supplied to patients on reasonable terms.

In Japan, compulsory licensing is primarily governed by the Patent Act (Act No. 121 of 1959). The legislation balances patent owners' intellectual property rights with public-interest requirements, including access to essential medicines.

Japan does not have a separate compulsory licensing statute exclusively for biologics. The ordinary patent licensing framework applies to qualifying biological inventions, manufacturing processes and related technologies.

2. PRINCIPAL LEGISLATIVE FRAMEWORK

A. Japanese Patent Act, 1959

The Patent Act establishes three important compulsory licensing mechanisms.

1. Article 83 – Non-working of Patented Inventions

Where a patented invention has not been sufficiently and continuously worked in Japan for three years or longer, an interested person intending to work the invention may request negotiations for a non-exclusive licence.

However, this provision generally becomes available only after four years have elapsed from the filing date of the patent application.

Relevance to biologics: If a patented biological medicine or relevant invention is not sufficiently implemented in Japan, the statutory non-working mechanism may become relevant, subject to its requirements.

2. Article 92 – Dependent Patents

Article 92 provides a compulsory licensing mechanism where the implementation of a patented invention involves another person's earlier patented invention.

It allows the parties to negotiate a non-exclusive licence and provides for an administrative award where the statutory conditions are met.

Relevance to biologics: This provision may become relevant where the development or commercialization of a subsequent biological invention depends on an earlier patented technology.

3. Article 93 – Public Interest

Article 93 is particularly important for life-saving biologics.

Where implementation of a patented invention is particularly necessary for the public interest, a person intending to implement the invention may request negotiations with the patent holder.

If negotiations fail or cannot be conducted, the applicant may request an administrative award from the Minister of Economy, Trade and Industry (METI).

The Minister considers the matter through the statutory procedure, including consultation with the Industrial Property Council.

Relevance to biologics: Article 93 may provide a legal route where access to a patented life-saving biologic is seriously inadequate and public-interest implementation is particularly necessary.

3. GOVERNMENTAL AUTHORITIES AND ADMINISTRATIVE OVERSIGHT

The following institutions have important responsibilities:

Japan Patent Office (JPO): Administers patent rights and compulsory licensing procedures under the Patent Act.

Ministry of Economy, Trade and Industry (METI): Handles public-interest compulsory licensing applications under Article 93.

Ministry of Health, Labour and Welfare (MHLW): Responsible for pharmaceutical policy, healthcare access and medical-product regulation.

Pharmaceuticals and Medical Devices Agency (PMDA): Evaluates the quality, safety and efficacy of biological medicines and other regulated medical products.

A compulsory patent licence does not automatically authorize the licensee to manufacture or market a biologic. The licensee must independently satisfy applicable pharmaceutical authorization, manufacturing quality and safety requirements.

4. CONDITIONS FOR COMPULSORY LICENSING OF LIFE-SAVING BIOLOGICS

An application involving a life-saving biologic should establish the relevant statutory grounds.

Important considerations include:

Public-health necessity: Evidence that the biologic is important for preventing serious illness, disability or death.

Insufficient availability: Evidence of inadequate supply or serious barriers to access.

Public-interest justification: Evidence demonstrating why implementation of the patented invention is particularly necessary.

Voluntary negotiations: Appropriate attempts to obtain a voluntary licence, where required.

Manufacturing capability: Evidence that the proposed licensee can meet pharmaceutical quality and regulatory requirements.

Proportionality: The proposed licence should be limited to the necessary purpose and scope.

Remuneration: The patent holder must receive appropriate financial compensation under the applicable legal framework.

The existence of a high medicine price alone does not automatically establish entitlement to a compulsory licence under Japanese law.

5. IMPORTANT CASE LAWS AND ADMINISTRATIVE PRECEDENTS

Japan has very limited precedent concerning compulsory licensing itself. Importantly, the following 2021–2024 proceeding was an administrative compulsory-licensing dispute, not a judicial judgment. Other decisions provide analogous principles concerning pharmaceutical patents, biosimilar competition and patent rights.

1. Vision Care and VC Cell Therapy v. RIKEN, Osaka University and Helios (2021–2024)

On 13 July 2021, Vision Care and VC Cell Therapy requested a compulsory non-exclusive licence under Article 93(2) concerning Patent No. 6518878. The patent concerned a method of producing retinal pigment epithelial cells derived from human induced pluripotent stem cells.

The applicants sought access to the patented technology for treatment-related activities. Following extensive administrative proceedings, the parties reached a settlement on 30 May 2024. The applicants were permitted to use the patent under specified conditions, and the compulsory-licensing application was withdrawn.

Relevance – Direct administrative precedent: This is Japan's first major public-interest compulsory-licensing proceeding under Article 93. It demonstrates how negotiations and settlement can resolve disputes involving important biomedical technologies without a final compulsory-licensing award.

2. Guanidinobenzoic Acid Derivatives Case (Supreme Court, 16 April 1999)

The Supreme Court considered whether generic pharmaceutical manufacturers could conduct regulatory testing during the patent term to obtain approval for commercialization after patent expiry.

The Court recognized the applicability of the experimental-use exception under Article 69(1) of the Patent Act.

Relevance – Analogous authority: Regulatory testing and preparation for generic or biosimilar market entry can occur within the statutory patent exception. This supports timely pharmaceutical competition without automatically requiring compulsory licensing.

3. BBS Automobile Wheels Case (Supreme Court, 1 July 1997)

The Supreme Court examined patent exhaustion and the effects of the first authorized sale of patented products.

Relevance – Analogous authority: The decision illustrates limitations on the exercise of patent rights after authorized commercialization. It is relevant to understanding the relationship between intellectual property protection and downstream access to medical products.

4. Ink Cartridge Case (Supreme Court, 8 November 2007)

The Court examined patent exhaustion and the circumstances in which subsequent commercial activities involving previously sold patented products may constitute infringement.

Relevance – Analogous authority: The judgment helps clarify the limits of patent enforcement and the circumstances in which downstream use of patented products remains legally permissible.

5. Pravastatin Sodium Case (Supreme Court, 5 June 2015)

The Supreme Court addressed the interpretation of product-by-process patent claims, particularly where a pharmaceutical product is defined through its manufacturing process.

Relevance – Analogous authority: The decision is important for biologics because manufacturing methods, product characteristics and patent claim interpretation can affect biosimilar development and commercialization.

6. Oxaliplatinum Case (Intellectual Property High Court, 20 January 2017)

The Court considered the scope of pharmaceutical patent protection during an extended patent term, including whether generic pharmaceutical products fell within the relevant extended patent rights.

Relevance – Analogous authority: It illustrates how extended patent protection may affect the availability of follow-on pharmaceutical products and the timing of market competition.

These six authorities should not be presented as six compulsory-licensing judgments. Only the Vision Care proceeding directly concerned an Article 93 compulsory-licensing application; the remaining five concern related patent-law principles.

6. INTERNATIONAL LEGAL FRAMEWORK

Japan's compulsory-licensing system must also be understood in the context of the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

A. TRIPS Article 31

Article 31 permits use of patented inventions without the patent holder's authorization, subject to specified safeguards.

These include:

Individual assessment of each application.

Appropriate limits on the scope and duration of authorization.

Non-exclusive licensing.

Adequate remuneration to the patent owner.

Review of the authorization and applicable terms.

Prior efforts to obtain voluntary authorization, subject to recognized exceptions.

B. Doha Declaration on TRIPS and Public Health (2001)

The Declaration confirms that WTO members may determine the grounds on which compulsory licences are granted and may identify national emergencies and circumstances of extreme urgency.

This provides important international support for public-health measures intended to improve access to essential medicines.

7. REGULATORY CHALLENGES FOR LIFE-SAVING BIOLOGICS

Compulsory licensing of biologics presents particular legal and technical challenges.

A. Manufacturing complexity

Biological medicines are often manufactured through complex processes. A patent licence alone may not provide access to manufacturing expertise, technical documentation or other necessary resources.

B. Biosimilar development

A compulsory licence does not automatically establish that a biosimilar satisfies Japanese regulatory requirements. The proposed product must undergo the applicable scientific and regulatory assessment.

C. Patent ownership disputes

Biological inventions may involve multiple patent holders, research institutions, universities and commercial manufacturers. Identifying all relevant patent rights is essential.

D. Commercial confidentiality

Manufacturing information and confidential technical knowledge may remain protected independently of the patent licence.

E. Patient safety

Any licensed manufacturer must maintain appropriate quality, safety and efficacy standards. Public-health urgency does not eliminate pharmaceutical regulatory obligations.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Organizations seeking compulsory licences for life-saving biologics in Japan should:

Identify the relevant patents and their ownership.

Establish the public-health necessity of the proposed licensing arrangement.

Document shortages or inadequate availability where relevant.

Initiate voluntary licensing negotiations under Article 93.

Maintain evidence of unsuccessful negotiations or circumstances preventing agreement.

Submit the appropriate application to METI under Article 93(2).

Provide evidence of manufacturing and regulatory capability.

Establish an appropriate remuneration proposal.

Obtain separate pharmaceutical manufacturing and marketing authorization where required.

Maintain biological-product quality assurance and post-marketing safety monitoring.

9. CONCLUSION

Japan's compulsory licensing framework for life-saving biologics is principally governed by Articles 83, 92 and 93 of the Patent Act. Article 93 is particularly significant because it permits compulsory non-exclusive licensing where implementation of a patented invention is particularly necessary for the public interest.

The Vision Care and VC Cell Therapy proceeding involving patented iPSC-derived retinal pigment epithelial cells represents an important development in Japanese biotechnology licensing. Although the matter concluded through settlement rather than a final compulsory-licensing award, it demonstrates the practical importance of Article 93 in resolving disputes involving medical innovation.

Japanese patent decisions concerning pharmaceutical testing, patent exhaustion, manufacturing claims and extended patent protection provide additional guidance. Internationally, TRIPS Article 31 and the Doha Declaration reinforce the legitimacy of compulsory licensing as a public-health instrument.

Ultimately, Japan seeks to balance pharmaceutical innovation, patent-holder rights, manufacturing quality and access to essential biological medicines. Compulsory licensing remains an important statutory mechanism for addressing exceptional public-interest needs while preserving appropriate intellectual property protections.